Hong Kong Stock Alert | VIVA BIOTECH (01873) Surges Over 10% in Afternoon Trading as AI Pharmaceutical Business Model Shows Validation, Company Takes Forward-Looking Approach in AI Drug Development

Stock News

Oct 08

VIVA BIOTECH (01873) surged over 10% in afternoon trading. As of press time, the stock rose 10.45% to HK$3.17, with trading volume reaching HK$32.0142 million. On the news front, multiple new AI pharmaceutical contracts have been added globally recently. Guoyuan International noted that VIVA BIOTECH has been positioning itself in AI pharmaceuticals since five years ago, with AI-related orders currently accounting for 12% of newly signed contracts and showing a growing trend. Huaxin Securities stated that VIVA BIOTECH's CRO business primarily serves the early stages of drug discovery, which is an important application scenario for AI that can enhance drug development efficiency and success rates. Therefore, the company launched an AI-integrated drug development platform called AIDD for its clients. As of the first half of 2025, AIDD has cumulatively participated in the development of 175 projects, with AI-enabled CRO business accounting for 10% of total revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1188508612"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188508612\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188508612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 14:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188508612","market":"fut","top_or_hot":-1,"title":"Hong Kong Stock Alert | VIVA BIOTECH (01873) Surges Over 10% in Afternoon Trading as AI Pharmaceutical Business Model Shows Validation, Company Takes Forward-Looking Approach in AI Drug Development","media":"Stock News","content":"<p>VIVA BIOTECH (01873) surged over 10% in afternoon trading. As of press time, the stock rose 10.45% to HK$3.17, with trading volume reaching HK$32.0142 million. On the news front, multiple new AI pharmaceutical contracts have been added globally recently. Guoyuan International noted that VIVA BIOTECH has been positioning itself in AI pharmaceuticals since five years ago, with AI-related orders currently accounting for 12% of newly signed contracts and showing a growing trend. Huaxin Securities stated that VIVA BIOTECH's CRO business primarily serves the early stages of drug discovery, which is an important application scenario for AI that can enhance drug development efficiency and success rates. Therefore, the company launched an AI-integrated drug development platform called AIDD for its clients. As of the first half of 2025, AIDD has cumulatively participated in the development of 175 projects, with AI-enabled CRO business accounting for 10% of total revenue.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | VIVA BIOTECH (01873) Surges Over 10% in Afternoon Trading as AI Pharmaceutical Business Model Shows Validation, Company Takes Forward-Looking Approach in AI Drug Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | VIVA BIOTECH (01873) Surges Over 10% in Afternoon Trading as AI Pharmaceutical Business Model Shows Validation, Company Takes Forward-Looking Approach in AI Drug Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-08 14:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VIVA BIOTECH (01873) surged over 10% in afternoon trading. As of press time, the stock rose 10.45% to HK$3.17, with trading volume reaching HK$32.0142 million. On the news front, multiple new AI pharmaceutical contracts have been added globally recently. Guoyuan International noted that VIVA BIOTECH has been positioning itself in AI pharmaceuticals since five years ago, with AI-related orders currently accounting for 12% of newly signed contracts and showing a growing trend. Huaxin Securities stated that VIVA BIOTECH's CRO business primarily serves the early stages of drug discovery, which is an important application scenario for AI that can enhance drug development efficiency and success rates. Therefore, the company launched an AI-integrated drug development platform called AIDD for its clients. As of the first half of 2025, AIDD has cumulatively participated in the development of 175 projects, with AI-enabled CRO business accounting for 10% of total revenue.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1188508612","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188508612","pubTimestamp":1759903578,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VIVA BIOTECH (01873) surged over 10% in afternoon trading. As of press time, the stock rose 10.45% to HK$3.17, with trading volume reaching HK$32.0142 million. On the news front, multiple new AI...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物","BK1141":"生命科学工具和服务","HSCEI":"国企指数","BK1576":"医药外包概念","01477":"欧康维视生物-B","BK4614":"Manus概念股","07226":"南方两倍做多恒科","BK1191":"制药","YANG":"三倍做空富时中国ETF-Direxion","BK1574":"生物医药B类股"},"translate_title":"港股快讯|维亚生物(01873)午后大涨超10%AI制药商业模式显示验证，公司在AI药物开发方面采取前瞻性做法","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01873":1,"07226":1,"HSCEI":1,"YANG":1},"content_text":"VIVA BIOTECH (01873) surged over 10% in afternoon trading. As of press time, the stock rose 10.45% to HK$3.17, with trading volume reaching HK$32.0142 million. On the news front, multiple new AI pharmaceutical contracts have been added globally recently. Guoyuan International noted that VIVA BIOTECH has been positioning itself in AI pharmaceuticals since five years ago, with AI-related orders currently accounting for 12% of newly signed contracts and showing a growing trend. Huaxin Securities stated that VIVA BIOTECH's CRO business primarily serves the early stages of drug discovery, which is an important application scenario for AI that can enhance drug development efficiency and success rates. Therefore, the company launched an AI-integrated drug development platform called AIDD for its clients. As of the first half of 2025, AIDD has cumulatively participated in the development of 175 projects, with AI-enabled CRO business accounting for 10% of total revenue.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}